NK cell-based immunotherapy in AML Despite these challenges, NK cell-based immunotherapies have shown promise in preclinical and clinical studies.

NY-ESO-1 TCR/IL-15 NK is the lead clinical program of Syena, a Replay and MD Anderson cell therapy company based on the scientific discoveries of Professor Katy Rezvani, M.D., Ph.D.

CAR-NK cell therapies are innovative therapeutic options developed for the purpose of overcoming some of the limitations associated with CAR-T cell therapies, such as therapy-induced side effects ...